Dr. Borad on the Next Steps for Research Evaluating RLY-4008 in FGFR2+ Cholangiocarcinoma

Mitesh Borad, MD, professor of Medicine, Mayo Clinic School of Medicine, program leader, Gene and Virus Therapy Program, director, Cancer Cell, Gene, and Virus (CGV) Therapy Lab, director, Liver and Biliary Cancer Research Program, Mayo Clinic, discusses the next steps for investigating RLY-4008 in cholangiocarcinoma harboring FGFR2 fusion or rearrangement.

Data from the phase 1/2 ReFocus trial (NCT04526106) presented at the 2022 ESMO Congress showed that RLY-4008 elicited an objective response rate of 88.2% in 17 patients with FGFR inhibitor–naïve cholangiocarcinoma who received the oral agent at the recommended phase 2 dose of 70 mg once daily.

A key next step for research will involve evaluating RLY-4008 in a larger cohort of patients, Borad says. Given the smaller cohort of patients examined thus far in the ReFocus trial, additional data from a larger population can shed additional light on response rates initially observed with the agent, Borad adds. Getting additional data on the agent in future studies will be vital, Borad concludes.